Skip to main content

Advertisement

Table 2 Multivariate logistic regression analysis for predictors of complete treatment within 1 year after beginning anti-tuberculosis (TB) treatment

From: Treatment delay and fatal outcomes of pulmonary tuberculosis in advanced age: a retrospective nationwide cohort study

  Number Completion rate Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
Implementation of DOTS
 Pre-DOTS era (2004–2005) 28,913 68.9% 1   1  
 DOTS era (2006–2009) 52,168 72.5% 1.19 (1.16, 1.23) <0.001 1.25 (1.21, 1.30) <0.001
Age (years)       <0.001
 20–34 9595 85.0% 1   1  
 35–49 13,319 79.1% 0.67 (0.63, 0.72) <0.001 0.84 (0.78, 0.91) <0.001
 50–64 17,347 75.3% 0.54 (0.51, 0.58) <0.001 0.81 (0.75, 0.87) <0.001
 65–79 26,897 68.3% 0.38 (0.36, 0.41) <0.001 0.69 (0.64, 0.74) <0.001
 80 and above 13,923 54.8% 0.21 (0.20, 0.23) <0.001 0.43 (0.40, 0.46) <0.001
Sex
 Female 24,914 71.7% 1   1  
 Male 56,167 71.0% 0.97 (0.93, 1.00) 0.033 1.15 (1.11, 1.19) <0.001
Comorbidities
 No 47,182 78.3% 1    
 Any 33,899 61.4% 0.44 (0.43, 0.45) <0.001   
Diabetes mellitus
 No 58,079 73.2% 1   1  
 Yes 23,002 66.3% 0.72 (0.70, 0.75) <0.001 0.93 (0.89, 0.96) <0.001
Chronic obstructive pulmonary disease
 No 74,449 73.2% 1   1  
 Yes 6632 48.8% 0.35 (0.33, 0.37) <0.001 0.53 (0.50, 0.56) <0.001
Malignancy
 No 74,017 73.5% 1   1  
 Yes 7064 47.3% 0.32 (0.31, 0.34) <0.001 0.38 (0.36, 0.41) <0.001
End-stage renal disease
 No 79,172 71.9% 1   1  
 Yes 1909 42.9% 0.29 (0.27, 0.32) <0.001 0.41 (0.37, 0.45) <0.001
Liver cirrhosis
 No 80,631 71.5% 1   1  
 Yes 450 31.1% 0.18 (0.15, 0.22) <0.001 0.21 (0.17, 0.27) <0.001
Autoimmune disease
 No 80,262 71.4% 1   1  
 Yes 819 59.6% 0.59 (0.51, 0.68) <0.001 0.69 (0.59, 0.81) <0.001
Acquired immunodeficiency syndrome
 No 80,632 71.3% 1   1  
 Yes 449 53.9% 0.47 (0.39, 0.57) <0.001 0.37 (0.30, 0.45) <0.001
Low income       
 No 78,213 71.4% 1   1  
 Yes 2868 66.5% 0.80 (0.73, 0.86) <0.001 0.86 (0.79, 0.95) 0.002
Hospital accreditation levels of initial visits
 Medical centers or regional hospitals 43,360 67.0% 1    
 Local hospitals or clinics 37,721 76.1% 1.57 (1.52, 1.62) <0.001 1.25 (1.20, 1.30) <0.001
Specialties of initial visits
 Pulmonologists or infection specialists 14,102 72.5% 1   1  
 Others 66,979 71.0% 0.93 (0.89, 0.97) <0.001 0.83 (0.79, 0.87) <0.001
Hospitalisation within 14 days of commencing anti-TB treatment
 No 38,809 82.0% 1   1  
 Yes 42,272 61.3% 0.35 (0.34, 0.36) <0.001 0.62 (0.60, 0.64) <0.001
Requiring intensive care within 14 days of commencing anti-TB treatment
 No 72,565 75.8% 1   1  
 Yes 8516 32.6% 0.16 (0.15, 0.16) <0.001 0.54 (0.50, 0.59) <0.001
Invasive ventilatory support within 14 days of commencing anti-TB treatment
 No 73,333 75.7% 1   1  
 Yes 7748 28.8% 0.13 (0.12, 0.14) <0.001 0.39 (0.36, 0.42) <0.001
Non-invasive ventilatory support within 14 days of commencing anti-TB treatment
 No 79,780 71.9% 1   1  
 Yes 1301 30.9% 0.18 (0.16, 0.20) <0.001 0.75 (0.66, 0.86) <0.001
Second-line anti-TB treatment ≥14 days       
 No 67,190 76.9% 1   1  
 Yes 13,891 44.0% 0.24 (0.23, 0.25) <0.001 0.29 (0.28, 0.31) <0.001
Delay in anti-TB treatment (per week)      0.992 (0.990, 0.994) <0.001
  1. DOTS directly observed treatment, short course, OR odds ratio, CI confidence interval